Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.

Inovio Pharmaceuticals Inc (INO) stock saw a decline, ending the day at $2.09 which represents a decrease of $-0.19 or -8.33% from the prior close of $2.28. The stock opened at $2.36 and touched a low ...

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report)‘s stock had its “market outperform” rating restated by JMP Securities ...

Stephens has recently initiated Inovio Pharmaceuticals Inc (INO) stock to Overweight rating, as announced on May 14, 2024, according to Finviz. Earlier, on January 25, 2024, Oppenheimer had raised the ...

Analysts at HC Wainwright upped their FY2024 earnings estimates for Inovio Pharmaceuticals in a research report issued on ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of ...

Inovio Pharmaceuticals Inc. closed $12.66 below its 52-week high ($14.75), which the company reached on April 1st.

Inovio Pharmaceuticals Inc. closed $12.47 short of its 52-week high ($14.75), which the company reached on April 1st.

PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...

Inovio Pharmaceuticals, Inc. is currently listed on NASDAQ under INO. One share of INO stock can currently be purchased for approximately $1.91. Is Inovio Pharmaceuticals, Inc. listed on the ...

Dino DiPerna, Senior Vice President of Global R&D at Ciena Corp (NYSE:CIEN), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. On ...